Pancreatic Cancer Research

ResearcherThe Affiliated Yongchuan Hospital of Chongqing Medical UniversityActive in the last 2 years

Shengchun Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9933-3643; OpenAlex author ID A5063891991. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 3

  1. Comprehensive pan-cancer analysis reveals CDC6 as a potential immunomodulatory agent and promising therapeutic target in pancreatic cancer. Last author DOI 10.21037/tcr-24-505↗
  2. Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer Patients. Last author DOI 10.1155/2022/2363043↗
  3. LACTB mRNA expression is increased in pancreatic adenocarcinoma and high expression indicates a poor prognosis. Last author DOI 10.1371/journal.pone.0245908↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yingkun Xu · 2 shared papers, 2022–2024 · strength 0.38
  2. Dongyao Pu · 1 shared paper, 2024 · strength 0.23
  3. Haochen Yu · 1 shared paper, 2024 · strength 0.23
  4. Xin Liu · 1 shared paper, 2022 · strength 0.15
  5. Jian Wei Xie · 1 shared paper, 2021 · strength 0.15
  6. Ze‐Lin Wen · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.